Science News
from research organizations

Studying therapeutic stool transplantation (fecal microbiota transplantation)

Date:
September 30, 2016
Source:
Deutsches Aerzteblatt International
Summary:
Patients suffering from infection of the bowel with the Gram-positive bacillus Clostridium difficile often have recurrent infections despite antibiotic treatment. In such cases, the transfer of stool from a healthy donor into the patient’s bowel is a safe and effective treatment option, concludes research.
Share:
FULL STORY

Patients suffering from infection of the bowel with the Gram-positive bacillus Clostridium difficile often have recurrent infections despite antibiotic treatment. In such cases, the transfer of stool from a healthy donor into the patient's bowel is a safe and effective treatment option. This is the conclusion of Stefan Hagel, Andreas Stallmach, Maria Vehreschild, and co-authors and of the members of the German Clinical Microbiome Study Group in their article in the current issue of the Deutsches Ärzteblatt International.

In a retrospective, multicenter, longitudinal observational study, the response rates to fecal microbiota transplantation as a treatment for recurrent C. difficile infection were determined a 30 and 90 days, and adverse events were registered. Primary cure was achieved at 30 days in 101 of 120 patients (84.2%), and at 90 days in 72 of 92 patients (78.3%). These figures improved further after a second microbiota transplantation in 19 of the patients. There were no severe adverse effects or deaths within 30 days of the treatment.

Fecal microbiota transplantation has not been approved by the regulatory authorities and can only be used in Germany as an individual treatment for C. difficile infection if all other treatments have failed. The authors call for more uniform documentation of the clinical efficacy and safety of fecal microbiota transplantation. For better quality assurance, the diverse protocols for patient selection, donor screening, and the processing and application of stool samples are in need of harmonization.


Story Source:

Materials provided by Deutsches Aerzteblatt International. Note: Content may be edited for style and length.


Journal Reference:

  1. Hagel S, Fischer A, Ehlermann P, Frank T, Tüffers K, Sturm A, Link A, Demir M, Siebenhaar A, Storr M, Glück T, Siegel E, Solbach P, Goeser F, Kölbel CB, Lohse A, Lübbert C, Kandzi U, Maier M, Schürle S, Lerch MM, Tacke D, Cornely OA, Stallmach A, Vehreschild MJGT, on behalf of the German Clinical Mircobiome Study Group (GCMSG). Fecal microbiota transplant in patients with recurrent Clostridium difficile infection—a retrospective multicenter observational study from the MicroTrans registry. Dtsch Arztebl Int, September 2016 DOI: 10.3238/arztebl.2016.0583

Cite This Page:

Deutsches Aerzteblatt International. "Studying therapeutic stool transplantation (fecal microbiota transplantation)." ScienceDaily. ScienceDaily, 30 September 2016. <www.sciencedaily.com/releases/2016/09/160930080720.htm>.
Deutsches Aerzteblatt International. (2016, September 30). Studying therapeutic stool transplantation (fecal microbiota transplantation). ScienceDaily. Retrieved May 26, 2017 from www.sciencedaily.com/releases/2016/09/160930080720.htm
Deutsches Aerzteblatt International. "Studying therapeutic stool transplantation (fecal microbiota transplantation)." ScienceDaily. www.sciencedaily.com/releases/2016/09/160930080720.htm (accessed May 26, 2017).

RELATED STORIES